Treatment with anti-CD19 CAR-T cells achieved durable responses in patients with relapsed and/or refractory (R/R) acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and diffuse large B cell lymphoma (DLBCL) (2–6). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.